Short Interest in Zhengye Biotechnology Holding Limited (NASDAQ:ZYBT) Drops By 38.5%

Zhengye Biotechnology Holding Limited (NASDAQ:ZYBT) saw a large decline in short interest in April. As of April 30th, there was short interest totaling 31,421 shares, a decline of 38.5% from the April 15th total of 51,122 shares. Approximately 0.1% of the company’s shares are sold short. Based on an average trading volume of 23,330 shares, the days-to-cover ratio is presently 1.3 days.

Analysts Set New Price Targets

Separately, Weiss Ratings downgraded Zhengye Biotechnology from a “sell (d)” rating to a “sell (d-)” rating in a research report on Friday. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company currently has a consensus rating of “Sell”.

Institutional Investors Weigh In On Zhengye Biotechnology

A number of hedge funds have recently added to or reduced their stakes in ZYBT. Citadel Advisors LLC acquired a new stake in shares of Zhengye Biotechnology in the 3rd quarter valued at $31,000. Millennium Management LLC acquired a new stake in shares of Zhengye Biotechnology in the 3rd quarter valued at $38,000. WINTON GROUP Ltd acquired a new stake in shares of Zhengye Biotechnology in the 3rd quarter valued at $56,000. Geode Capital Management LLC acquired a new stake in shares of Zhengye Biotechnology in the 2nd quarter valued at $174,000. Finally, Invesco Ltd. acquired a new stake in shares of Zhengye Biotechnology in the 2nd quarter valued at $220,000.

Zhengye Biotechnology Stock Down 4.1%

Zhengye Biotechnology stock traded down $0.04 during mid-day trading on Tuesday, reaching $0.89. 9,452 shares of the company’s stock were exchanged, compared to its average volume of 155,726. Zhengye Biotechnology has a twelve month low of $0.68 and a twelve month high of $13.08. The company has a debt-to-equity ratio of 0.03, a current ratio of 1.14 and a quick ratio of 0.82. The company has a fifty day moving average of $0.92 and a 200-day moving average of $1.30.

Zhengye Biotechnology (NASDAQ:ZYBT) last released its earnings results on Tuesday, April 28th. The company reported ($0.08) earnings per share (EPS) for the quarter. The business had revenue of $3.97 million for the quarter.

Zhengye Biotechnology Company Profile

Zhengye Biotechnology Holding Limited is a veterinary vaccine manufacturer which encompasses research, development, manufacturing and sales of veterinary vaccines, with a focus on livestock vaccine principally in China. Zhengye Biotechnology Holding Limited is based in Jilin, China.